Anti-MDR tumor mechanism of CIP-36, a podophyllotoxin derivative

Yaoxue Xuebao

Volumn 46, Issue 10, 2011, Pages 1193-1198

  Mei, Xin ^a,b   Jiang, Yun Gen ^b   Lü, Jing Jing ^c   Wu, Ke Zhu ^b   Cao, Bo ^a   Chen, Hong ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Pharmacy Department   (China)

^c CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd   (China)

Author keywords

CIP 36; Multidrug resistance; P glycoprotein; Podophyllotoxin derivative

Indexed keywords

CASPASE 3; CIP 36; HOE 33342; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PODOPHYLLOTOXIN DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; KB CELLS; MOUTH NEOPLASMS; P-GLYCOPROTEIN; PODOPHYLLOTOXIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 83455172632     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. World Health Organization. A safer future [R]. Geneva: WHO, 2009.
2. He Y, Ma WY, Chen XH, et al. Synthesis and activities of 4-deoxy-4β-arylmehtylene sulfonylamido-4′-demethylpodophyllotoxins [J]. Acta Pharm Sin, 2001, 36: 105-107.
3. Issell BF. The podophyllotoxin derivatives VP16-213 and VM26 [J]. Cancer Chemother Pharmacol, 1982, 7: 73-80. (Pubitemid 12156997)
4. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance [J]. J Clin Oncol, 1992, 10: 1635-1642. (Pubitemid 23057994)
5. Ji SY, Weng ZY, Zhou YP, et al. The cytotoxicity of some organic solvents in common use on human tumor cell lines 8 [J]. J Yunnan Univ, 2001, 23: 457-460.
6. Lü JJ, Zhang YY, Chen H, et al. CIP-36, a novel podophyllotoxin derivative, induces the apoptosis of KBV200 cells [J]. Chin Pharmacol Bull, 2010, 26: 607-610.
7. Meresse P, Dechaux E, Bertounesque E, et al. Etoposide: discovery and medicinal chemistry [J]. Curr Med Chem, 2004, 11: 2443-2466. (Pubitemid 39172359)
8. Yu T, Zhao GS, Zang HL, et al. Advances in tumor multidrug resistance reversal agents [J]. Chin J Med Chem, 2003, 13: 172-178.
9. El-Deiry WS, Tokino T, Velculescv VE, et al. WAF1, a potential mediator of p53 tumour suppression [J]. Cell, 1993, 75: 817-823.
10. Chin KV, Ueda K, Pastan I, et al. Modulation of the promoter of the human mdr1 gene by ras and p53 [J]. Science, 1992, 255: 459-464.
11. Zhang Y, Goodyer C, LeBlanc A. Selective and protracted apoptosis in human primary neurons microinjected with active caspase-3, -6, -7 and -8 [J]. J Neurosci, 2000, 20: 8384-8389.
12. Cryns V, Yuan J. Protease to die for [J]. Genes Dev, 1998, 12: 1551-1570.
13. Wu J, Lu H, Xue QJ, et al. Advance of Bcl-2 genes [J]. World Chin J Digestol, 2004, 12: 2171-2173.